Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Virology

• Publication date

  2015-09-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.02131-15PMID 26378179PMCID PMC4645305
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Raltegravir or Elvitegravir Resistance Signature Mutations on the Barrier to Dolutegravir Resistance In Vitro

  2015cited by this paper
• A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

  2015cited by this paper
• Simian-Tropic HIV as a Model To Study Drug Resistance against Integrase Inhibitors

  2015influential reference
• Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions

  2015cited by this paper
• Postexposure Protection of Macaques from Vaginal SHIV Infection by Topical Integrase Inhibitors

  2014cited by this paper
• Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.

  2014cited by this paper
• Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection

  2014cited by this paper
• Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase

  2014cited by this paper
• Roles of HIV-1 capsid in viral replication and immune evasion.

  2014cited by this paper
• Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus

  2014influential reference
• Effect of HIV-1 Integrase Resistance Mutations When Introduced into SIVmac239 on Susceptibility to Integrase Strand Transfer Inhibitors

  2014influential reference
• Integrase strand transfer inhibitors in the management of HIV-positive individuals

  2014cited by this paper
• Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase

  2014cited by this paper
• Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

  2014cited by this paper
• Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

  2013cited by this paper
• Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

  2013cited by this paper
• Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase

  2013influential reference
• Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

  2013cited by this paper
• A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescence.

  2012cited by this paper
• HIV DNA integration.

  2012cited by this paper
• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

  2012cited by this paper
• In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

  2012influential reference
• Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations

  2012cited by this paper
• A Single Dose of a MIV-150/Zinc Acetate Gel Provides 24 h of Protection Against Vaginal Simian Human Immunodeficiency Virus Reverse Transcriptase Infection, with More Limited Protection Rectally 8–24 h After Gel Use

  2012cited by this paper
• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

  2012cited by this paper
• Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

  2012cited by this paper
• Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.

  2011cited by this paper
• HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications

  2011influential reference
• Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

  2011influential reference
• Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations

  2011cited by this paper
• Durable Protection from Vaginal Simian-Human Immunodeficiency Virus Infection in Macaques by Tenofovir Gel and Its Relationship to Drug Levels in Tissue

  2011cited by this paper
• G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not

  2011cited by this paper
• Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor

  2010cited by this paper
• HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays

  2010cited by this paper
• Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy

  2010cited by this paper
• The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions

  2010cited by this paper
• In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

  2010influential reference
• Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy

  2010cited by this paper
• Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates

  2010cited by this paper
• Evaluation of antiretrovirals in animal models of HIV infection.

  2010cited by this paper
• Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes

  2009cited by this paper
• Isolation of drug-resistant mutant HIV variants using tissue culture drug selection.

  2009influential reference
• Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies

  2009cited by this paper
• Integrase and integration: biochemical activities of HIV-1 integrase

  2008cited by this paper
• Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

  2008cited by this paper
• Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel

  2008cited by this paper
• Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir

  2008cited by this paper
• Construction and infection of a new simian/human immunodeficiency chimeric virus (SHIV) containing the integrase gene of the human immunodeficiency virus type 1 genome and analysis of its adaptation to monkey cells.

  2008cited by this paper
• Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection

  2007cited by this paper
• Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137)

  2007cited by this paper
• Kinetic study of the HIV−1 DNA 3′‐end processing

  2006cited by this paper
• CD8+-Cell-Mediated Suppression of Virulent Simian Immunodeficiency Virus during Tenofovir Treatment

  2004cited by this paper
• Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis

  2004cited by this paper
• Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques

  2004cited by this paper
• Molecular Cloning: A Laboratory Manual

  2001cited by this paper
• Protein identification and analysis tools in the ExPASy server.

  1999cited by this paper
• Purification, solution properties and crystallization of SIV integrase containing a continuous core and C-terminal domain.

  1999cited by this paper
• Structure-Based Mutational Analysis of the C-Terminal DNA-Binding Domain of Human Immunodeficiency Virus Type 1 Integrase: Critical Residues for Protein Oligomerization and DNA Binding

  1998cited by this paper
• Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

  1997cited by this paper
• Biophysical and enzymatic properties of the catalytic domain of HIV-1 integrase.

  1994cited by this paper
• The kinetics of enzyme-catalyzed reactions with two or more substrates or products. I. Nomenclature and rate equations. 1963.

  1989cited by this paper
• Partition analysis and the concept of net rate constants as tools in enzyme kinetics.

  1975cited by this paper
• The kinetics of enzyme-catalyzed reactions with two or more substrates or products. I. Nomenclature and rate equations.

  1963cited by this paper

• Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection

  2019cites this paper
• Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes

  2018influential citation
• Emergence of resistance mutations in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving non-suppressive antiretroviral therapy (ART)

  2018cites this paper
• Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1

  2017cites this paper
• HIV-1 Resistance to Integrase Inhibitors

  2017cites this paper
• Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review

  2016influential citation
• Caractérisation de l’effet des inhibiteurs allostériques de l’interaction IN-LEDGF/p75 (INLAIs) sur la réplication du VIH-1 et du SIV

  2016cites this paper